FrancophonIA/ELRC3.0 huggingface dataset:
English: Ritonavir was not found to be mutagenic or clastogenic in a battery of in vitro and in vivo assays including the Ames bacterial reverse mutation assay using S. typhimurium and E. coli, the mouse lymphoma assay, the mouse micronucleus test and chromosomal aberration assays in human lymphocytes.
Maltese: F'serje sħiha ta' provi in vitro u in vivo inkluża l-prova ‘Ames bacterial reverse mutation' bl-użu ta' S. typhimurium u ta' E. coli, il-prova tal-linfoma fil-ġurdien, it-test mikronukleju fil-ġurdien u provi ta' aberrazzjoni kromosomali f'linfoċiti umani, ma ġiex misjub li ritonavir huwa mutaġeniku jew klastoġeniku.
English: Ritonavir has a high affinity for several cytochrome P450 (CYP) isoforms and may inhibit oxidation with the following ranked order: CYP3A4 > CYP2D6.
Maltese: Ritonavir għandu affinità għolja għal diversi isoformi ta'ċitokromi P450 (CYP) u jista' jimpedixxi l-ossidazzjoni skond din l-ordni li ġejja:
English: In a study completed in 1996 recruiting less advanced HIV-1 infected patients (CD4 200-500 cells/μl) without previous antiretroviral therapy, ritonavir in combination with zidovudine or alone reduced viral load in plasma and increased CD4 count.
Maltese: Fi studju komplet fl-1996 li fih ħadu sehem pazjenti infettati bl-HIV però fi stadju inqas avanzat talmarda (CD4 200 - 500 ċellula/µl) u li ma kinux ingħataw terapija antiretrovirali qabel, ritonavir flimkien ma' zidovudine jew waħdu naqqas it-tagħbija virali fil-plażma u żid l-għadd ta' CD4.
English: 500q12h ↑ 3.4-fold ↑ 55% Ritonavir inhibits CYP3A-mediated metabolism of ketoconazole.
Maltese: Ritonavir jimpedixxi l-metaboliżmu medjat b' CYP3A ta' ketoconazole.
English: In a clinical study investigating the interaction of rifampicin 600 mg once daily and saquinavir 1,000 mg with ritonavir 100 mg twice daily in healthy volunteers, severe hepatocellular toxicity with transaminase elevations up to > 20-fold the upper limit of normal after 1 to 5 days of co-administration was noted.
Maltese: Fi studju kliniku li sar fuq voluntiera f'saħħithom fejn kienet qiegħda tiġi investigata l-interazzjoni ta' 600 mg rifampicin darba kuljum u 1000 mg saquinavir flimkien ma' 100 mg ritonavir darbtejn kuljum, wara li kienu għaddew minn ġurnata sa 5 ġranet ta' għoti tal-mediċini flimkien, ġiet innotata tossiċità epatoċellulari severa b'żidied fit-transaminase sa >20-darba mill-ogħla limitu normali.
English: In a study completed in 2000, 76 HIV-1 infected children aged 6 months to 12 years who were protease inhibitor naive and naive to lamivudine and/or stavudine received ritonavir 350 or 450 mg/m2 every 12 hours co-administered with lamivudine and stavudine.
Maltese: Fi studju komplet fl-2000, 76 tifel u tifla ta' età ta' bejn 6 ġimgħat u 12 il-xagħar, li kienu infettati b'HIV-1 u li kienu naive għal inibituri protejaż u naive għal lamivudine u/jew stavudine, irċevew ritonavir 350 or 450 mg/m² kull 12 il-siegħa mogħtija ma lamivudine u stavudine.
English: A higher frequency of adverse reactions (e.g., dizziness, nausea, paraesthesia) and laboratory abnormalities (elevated liver enzymes) have been observed when efavirenz is co-administered with ritonavir dosed as an antiretroviral agent.
Maltese: Frekwenza ogħla ta' reazzjonijiet avversi (e.ż., sturdament, nawseja, parasteżija) u abnormalitajiet fir-riżultati tal-laboratorju (enzimi tal-fwied għoljin) ġew innotati meta efavirenz jingħata ma' ritonavir f'doża bħala aġent antiretrovali.
English: In a study completed in 2003, 50 HIV-1 infected, protease inhibitor and lamivudine naïve children age 4 weeks to 2 years received ritonavir 350 or 450 mg/m every 12 hours co-administered with zidovudine 160 mg/m every 8 hours and lamivudine 4 mg/kg every 12 hours.
Maltese: Fi studju komplet fl-2003, 50 tifel u tifla ta' età ta' bejn 4 ġimgħat u sentejn, li kienu infettati b'HIV-1 u qatt ma kienu esponew ruħom għal impedituri protejaż u lamivudine, kienu qegħdin jirċievu 350 jew 450 mg/m² ritonavir kull 12-il siegħa flimkien ma' 160 mg/m² zidovudine kull 8 siegħat u 4 mg/kg lamivudine kull 12-il siegħa.
English: Effects on the electrocardiogram
Maltese: Effetti fuq l-Elettrokardjogramm
English: Ritonavir steady-state pharmacokinetic parameters were evaluated in HIV infected children above 2 years of age receiving doses ranging from 250 mg/m2 twice daily to 400 mg/m2 twice daily.
Maltese: Il-parametri farmakokinetiċi fissi ta' ritonavir ġew evalwati fi tfal infettati bl-HIV ta'età ta' iżjed minn sentejn, li kienu qegħdin jirċievu dożi li jvarjaw minn 250 mg/m² darbtejn kuljum għal 400 mg/m² darbtejn kuljum.
English: Thyroid hormone replacement therapy
Maltese: Terapija ta' sostituzzjoni ta' ormon tat-tirojde
English: 300 q12 h, 3 days
Maltese: IV 300 q12 h, 3 jiem
English: Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and ritonavir (CYP3A4 and P-gp inhibition) in patients with renal and/or hepatic impairment (see sections 4.3 and 4.4).
Maltese: Ġew irrappurtati interazzjonijiet ma' prodotti mediċinali oħra, li jistgħu jipperikolaw il-ħajja u oħrajn fatali, f'pazjenti kkurati b'colchicine u ritonavir (inibizzjoni ta' CYP3A u P-gp) f'pazjenti b'indeboliment renali u / jew epatiku (ara sezzjonijiet 4.3 u 4.4).
English: Cardiac and neurologic events have been reported when ritonavir has been co-administered with disopyramide, mexiletine or nefazodone.
Maltese: Effetti kardijaċi u newroloġiċi ġew irrapportati meta ritonavir ingħata flimkien ma' disopyramide, mexiletine jew nefazodone.
English: Uncommon Rare oedema and peripheral oedema, dehydration (usually associated with gastrointestinal symptoms) Diabetes mellitus Hyperglycaemia
Maltese: Iperkolesterolemija, ipertrigliċeridemija, gotta, edima u edima periferali, deidrazzjoni (normalment assoċjata ma' sintomi gastrointestinali)
English: • dizziness
Maltese: • dijabete
English: Ritonavir 100 mg twice daily with saquinavir 1,000 mg twice daily provides saquinavir systemic exposure over 24 hours similar to or greater than those achieved with saquinavir 1,200 mg three times daily without ritonavir.
Maltese: Saquinavir għandu jingħata biss flimkien ma' ritonavir. 100 mg ritonavir darbtejn kuljum flimkien ma' 1000 mg saquinavir darbtejn kuljum jipprovdu esponiment sistemiku fuq 24 siegħa li huwa simili jew ikbar minn dak li jirrizulta b'1200 mg saquinavir tliet darbiet kuljum, mingħajr ritonavir.
English: No subject experienced an increase in QTcF of ≥ 60 msec from baseline or a QTcF interval exceeding the potentially clinically relevant threshold of 500 msec.
Maltese: L-ebda suġġett ma ġarrab żieda fil-QTcF li hi ≥60 msec mil-linja bażi jew intervall QTcF li jeċċedi l-limitu li hu potenzjalment klinikament rilevanti ta' 500 msec.
English: Due to the risk of QTc prolongation associated with DM-6705, if co-administration of delamanid with ritonavir is considered necessary, very frequent ECG monitoring throughout the full delamanid treatment period is recommended (see section 4.4 and refer to the delamanid Summary of Product Characteristics)
Maltese: Minħabba r-riskju ta' titwil tal-QTc assoċjati ma' DM 6705, jekk l-ko-amministrazzjoni ta' delamanid ma' ritonavir hija kkunsidrata neċessarja, huwa rrakkomandat monitoraġġ frekwenti ħafna ta' ECG matul il-perjodu kollu tat-trattament ta' delamanid (ara sezzjoni 4.4 u rreferi għasSommarju tal-Karatteristiċi tal-Prodott ta' delamanid).
English: Tablet dose
Maltese: Doża tal-pilloli
English: Steroids (e.g. dexamethasone, fluticasone propionate, prednisolone, triamcinolone) as ritonavir may raise the blood levels of these medicines which may lead to Cushing's syndrome (development of a rounded face) and reduce production of the hormone cortisol.
Maltese: - Sterojdi (e.ż. dexamethasone, fluticasone propionate, prednisolone, triamcinolone) għax ritonavir jista' jżid il-livelli fid-demm ta' dawn il-mediċini li jista' jwassal għas-sindromu Cushing (Cushing's syndrome) (żvilupp ta' wiċċ tond) u jnaqqas il-produzzjoni tal-ormon cortisol.
English: Hormonal contraceptives containing ethinylestradiol as ritonavir may reduce the effectiveness of these medicines.
Maltese: - Kontraċettivi li fihom l-ormoni li fihom ethinylestradiol għax ritonavir jista' jnaqqas l-effettività ta' dawn il-mediċini.
English: For a description of the mechanisms and potential mechanisms contributing to the interaction profile of the PIs, see section 4.5.
Maltese: Għal deskrizzjoni tal-mekkaniżmi u mekkaniżmi potenzjali li jikkontribwixxu għall-profil ta' interazzjonijiet tal-PIs, ara sezzjoni 4.5.
English: This increase is likely due to ritonavir and a more pronounced effect may be observed during prolonged co-administration.
Maltese: Din iż-żieda hija probabli minħabba ritonavir u effett aktar evidenti jista' jiġi osservat waqt ko-amministrazzjoni prolongata.
English: 400 q12 h Saquinavir4 Ritonavir
Maltese: 400 q112 h Saquinavir4 ↑ bi 17-il darba MD
English: Insomnia, anxiety, confusion, disturbance in attention, syncope, seizure
Maltese: Nuqqas ta' rqad, ansjetà, konfużjoni, nuqqas t'attenzjoni, sinkope, attakk tal-epilessija
English: Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice daily with ritonavir 100 mg twice daily.
Maltese: Provi kliniċi kkonfermaw issigurtà u l-effikaċja ta' 700 mg fosamprenavir darbtejn kuljum ma' 100 mg ritonavir darbtejn kuljum.
English: Ritonavir dosed as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is expected to increase concentrations of imipramine, amitriptyline, nortriptyline, fluoxetine, paroxetine or sertraline.
Maltese: X'aktarx li ritonavir f'doża bħala aġent antiretrovirali jimpedixxi CYP2D6 u għalhekk huwa mistenni li jżid il-konċentrazzjoni ta' imipramine, amitriptyline, nortriptyline, fluoxetine, paroxetine jew sertraline.
English: Increased plasma concentrations of astemizole and terfenadine.
Maltese: Astemizole, terfenadine Żieda fil-konċentrazzjoni fil-plażma ta' astemizole u terfenadine.
English: 100 mg once daily
Maltese: 100 mg darba kuljum
English: Ritonavir, co-administration is likely to result in increased plasma concentrations of amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, and quinidine and is therefore contraindicated (see section 4.3).
Maltese: It-teħid ta' ritonavir flimkien ma' amiodarone, bepridil, encainide, flecanide, propafenone u quinidine x'aktarx li jwassal għal żieda filkonċentrazzjoni fil-plażma ta' amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone u quinidine, u għalhekk huwa kontroindikat (ara sezzjoni 4.3).
English: Immune reconstitution inflammatory syndrome
Maltese: Sindromu ta' rikostruzzjoni infjammatorja tal-imunità
English: ↑ 14 fold
Maltese: ↑ b'14-il darba
English: ↑ 3-7 fold
Maltese: ↑ bi 4.7 drabi
English: • if your doctor prescribes a full dose, adults may be started on a dose of 3 tablets in the morning and 3 tablets 12 hours later, gradually increasing over a period of up to 14 days to the full dose of 6 tablets twice daily (totalling 1,200 mg per day).
Maltese: • jekk it-tabib tiegħek jagħtik doża sħiħa, l-adulti jistgħu jibdew fuq doża ta' 3 pilloli filgħodu u 3 pilloli 12-il siegħa wara, u bil-mod il-mod iżidu, fuq perijodu ta' żmien sa 14-il ġurnata, għal doża sħiħa ta' 6 pilloli darbtejn kuljum (li jammontaw għal total ta' 1,200 mg kuljum).
English: Therefore, combination of bedaquiline with ritonavir should be avoided.
Maltese: Għalhekk, kombinazzjoni ta' bedaquiline ma' lopinavir/ritonavir għandu jiġi evitat.
English: Ritonavir was noted to be extensively metabolised by the hepatic cytochrome P450 system, primarily by the CYP3A isozyme family and to a lesser extent by the CYP2D6 isoform.
Maltese: Ġie innutat li ritonavir jiġi fil-biċċa l-kbira tiegħu metabolizzat mis-sistema epatika cytochrome P450, primarjament mill-familja tal-iżożima CYP3A, u b'mod inqas mill-iżoforma CYP2D6.
English: The mean changes from baseline in PR interval ranged from 11.0 to 24.0 msec in the 12 hour interval post dose.
Maltese: Fl-intervall ta' 12-il siegħa wara li ngħatat id-doża, it-tibdil medju mil-linja bażi fl-intervall PR varja minn 11.0 sa 24.0 msec.
English: Ritonavir steady-state pharmacokinetic parameters were evaluated in HIV infected children less than 2 years of age receiving doses ranging from 350 to 450 mg/m2 twice daily.
Maltese: Il-parametri farmakokinetiċi fi stat fiss ta' ritonavir ġew evalwati fi tfal ta'età ta' inqas minn sentejn infettati bl-HIV, li kienu qegħdin jirċievu dożi li jvarjaw minn 350 sa 450 mg/m² darbtejn kuljum.
English: If treatment with an HMGCoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5).
Maltese: Jekk tkun indikata kura b'impeditur HMG-CoA reductase, pravastatin jew fluvastatin huma rrakkomandati (ara sezzjoni 4.5).
English: A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g., beclomethasone).
Maltese: Għandu jiġi kkunsidrat tnaqqis fid-doża tal-glucocorticoid u ssir osservazzjoni mill-qrib tal-effetti lokali u sistematiċi, jew jingħata glucocorticoid ieħor minflok, li m'huwiex sustanza li fuqa taħdem is-CYP3A4 (e.ż., beclomethasone).
English: This interaction may be due to modification of P-glycoprotein mediated digoxin efflux by ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
Maltese: Din l-interazzjoni tista' tkun ikkaġunata mill-modifikazzjoni ta' effluss ta' digoxin medjat b'P-glycoprotein minn ritonavir f'doża bħala aġent antiretrovirali jew biex iżid l-effett farmakokinetiku.
English: ↑ 2 fold
Maltese: Mhux komuni
English: Česká republika Mylan Healthcare CZ s.r.o.
Maltese: Mylan Healthcare s.r.o.
English: Increased plasma concentrations of clorazepate, diazepam, estazolam, flurazepam, oral midazolam and triazolam.
Maltese: Żieda fil-konċentrazzjoni fil-plażma ta' clorazepate, diazepam, estazolam, flurazepam, midazolam mittieħed mill-ħalq u triazolam.
English: Co-administration of tipranavir with 200 mg of ritonavir has been associated with reports of clinical hepatitis and hepatic decompensation including some fatalities.
Maltese: L-għoti ta' tipranavir ma' 200 mg ta' ritonavir, ġie assoċjat ma' rapporti ta' epatite klinika u dikompensazzjoni epatika, inkluż xi fatalitajiet.
English: Midazolam is extensively metabolised by CYP3A4.
Maltese: Midazolam huwa fil-biċċa l-kbira tiegħu metabolizzat b'CYP3A4.
English: Each film-coated tablet contains 100 mg ritonavir.
Maltese: Kull pillola miksija b'rita fiha 100 mg ritonavir.
English: Based on comparison to historical data, the pharmacokinetics of delavirdine did not appear to be affected by ritonavir.
Maltese: Meta bbażata fuq tqabbil ma' informazzjoni storika, il-farmakokinetika ta' delavirdine ma dehrux li huma affetwati minn ritonavir.
English: In a healthy volunteer drug interaction study of delamanid 100 mg twice daily and lopinavir/ritonavir 400/100 mg twice daily for 14 days, the
Maltese: Fi studju ta' interazzjoni tal-mediċina fuq voluntier b'saħħtu, b'100mg delamanid 100mg darbtejn kuljum u lopinavir/ritonavir 400/100 mg darbtejn kuljum għal 14-il ġurnata, l-espożizzjoni tal-metabolit ta'delamanid DM-6705 kien 30% miżjud.
English: 2 Based on cross-study comparison to 1,200 mg amprenavir twice daily alone.
Maltese: 2 Ibbażat fuq studju komparattiv li jinqeleb ma' 1200 mg amprenavir darbtejn kuljum waħdu.
English: 20, single dose 200q12h ↑ 124% ↔ The concomitant use of tadalafil for the treatment of erectile dysfunction with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer should be with caution at reduced doses of no more than 10 mg tadalafil every 72 hours with increased monitoring for adverse reactions (see section 4.4).
Maltese: L-użu flimkien ta' tadalafil ma' ritonavir għat-trattament tal-problema talerezzjoni tal-pene dożat bħala aġent antiretrovirali jew biex iżid l-effett farmakokinetiku għandu jsir b'attenzjoni u b'dożi mnaqqsa ta' mhux iktar minn 10 mg ta' tadalafil kull 72 siegħa, u għandu jkun hemm aktar osservazzjoni għal reazzjonijiet avversi (ara sezzjoni 4.4).
English: HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
Maltese: L-impedituri HMG-CoA reductase li huma dipendenti ħafna fuq ilmetaboliżmu b' CYP3A, bħal lovastatin u simvastatin huma mistennija li jkollhom żieda sostanzjali fil-konċentrazzjoni fil-plażma meta dawn jingħataw flimkien ma' ritonavir dożat bħala aġent antiretrovirali jew biex iżid l-effett farmakokinetiku.
English: Ritonavir pharmacokinetic parameters were not statistically significantly associated with body weight or lean body mass. Ritonavir plasma exposures in patients 50 - 70 years of age when dosed 100 mg in combination with lopinavir or at higher doses in the absence of other protease inhibitors is similar to that observed in younger adults.
Maltese: L-esponimenti fil-plażma b'ritonavir f'pazjenti ta' bejn 50 - 70 sena meta dożati b'100 mg jew dożi akbar flimkien ma' lopinavir, huma simili għallesponimenti osservati f'adulti iżgħar meta ma jkunx hemm impedituri ta' protejaż oħra.
English: Increased glucose, increased magnesium, increased alkaline phosphatase
Maltese: Żieda fil-glukows, żieda fil-manjesju, żieda fl-alkaline phosphatase
English: QTcF interval was evaluated in a randomised, placebo and active (moxifloxacin 400 mg once daily) controlled crossover study in 45 healthy adults, with 10 measurements over 12 hours on Day 3.
Maltese: L-intervall QTcF ġie evalwat fi studju tat-tip crossover li sar b'ordni addoċċ li kien ikkontrollat millplaċebo u attiv (moxifloxacin 400mg darba kuljum) li sar fuq 45 adult f'saħħtu, fejn f'Ġurnata 3, ġie mkejjel 10 darbiet fi 12-il siegħa.
English: rifabutin (used to prevent/treat certain infections)*; voriconazole (used to treat fungal infections)*; simvastatin, lovastatin (used to lower blood cholesterol); neratinib (used to treat breast cancer); lomitapide (used to lower blood cholesterol); alfuzosin (used to treat enlarged prostate gland); fusidic acid (used to treat bacterial infections); sildenafil if you suffer from a lung disease called pulmonary arterial hypertension that makes breathing difficult.
Maltese: - cisapride (użat biex itaffi ċerti problemi fl-istonku); - rifabutin (użat biex jippreveni / jikkura ċerti infezzjonijiet)*; - voriconazole (użat biex jikkura infezzjonijiet tal-fungu)*; - simvastatin, lovastatin (użati biex inaqqsu l-kolesterol fid-demm); - neratinib (użat biex jittratta kanċer tas-sider); - lomitapide (użat biex inaqqas il-kolesterol fid-demm); - alfuzosin (użati biex jikkuraw it-tkabbir tal-glandola tal-prostata); - fusidic acid (użat biex jikkura infezzjonijiet bil-batterji); - sildenafil jekk int tbati minn marda tal-pulmun li tissejjaħ pressjoni għolja fl-arterji pulmonari li tagħmilha diffiċli biex tieħu n-nifs.
English: Herbal preparations containing St John's wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of ritonavir (see section 4.5).
Maltese: Preparazzjonijiet tal-ħxejjex li jinkludu l- fexfiex tar-raba'(Hypericum perforatum) minħabba riskju ta' tnaqqis ta' konċentrazzjoni fil-plażma u tnaqqis fl-effetti kliniċi ta' ritonavir (ara sezzjoni 4.5).
English: A case of renal failure with eosinophilia has been reported.
Maltese: Ġie rrapportat każ ta' indeboliment renali bl-eżinofilja.
English: Clinical trials confirmed the safety and efficacy of 300 mg atazanavir once daily with ritonavir 100 mg once daily in treatment experienced patients.
Maltese: Provi kliniċi kkonfermaw is-sigurtà u l-effikaċja ta' 300 mg atazanavir darba kuljum ma' 100 mg ritonavir darba kuljum fuq pazjenti li għandhom esperjenza tat-trattament.
English: Medicinal Product Class
Maltese: Klassi tal-Prodott Mediċinali
English: Sorbitan laurate Silica, colloidal anhydrous Sodium chloride Sodium stearyl fumarate
Maltese: Sodium stearyl fumarate
English: Medicinal Products within Class
Maltese: Prodotti Mediċinali f'din il-Klassi
English: The concomitant administration with lurasidone is contraindicated (see section 4.3).
Maltese: L-għoti flimkien ma' lurasidone huwa kontraindikat (ara sezzjoni 4.3).
English: Ritonavir is used in combination with other anti-HIV medicines (antiretrovirals) to control your HIV infection.
Maltese: Ritonavir huwa wżat flimkien ma' mediċini oħra għal kontra l-HIV (antiretrovirali) biex jikkontrollalalek l-infezzjoni tal-HIV.
English: Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3 - 4 fold increase in midazolam plasma levels.
Maltese: Informazzjoni li ħarġet mill-użu ta' midazolam perenterali flimkien ma' impedituri protejażi oħra tissuġġerixxi żieda fil-livelli filplażma ta' midazolam li tista' tkun possibilment 3 - 4 darbiet aktar.
English: 50, single dose 600q12h ↑ 13-fold ↑ 2.4-fold Concomitant use of avanafil with ritonavir is contraindicated (see section 4.3).
Maltese: ↑ 13-il darba L-użu ta' vardenafil ma' ritonavir huwa kontra-indikat (ara sezzjoni 4.3).
English: 600 q12 h 2 h later
Maltese: 600 q12 h 2 h wara
English: morphine and morphine-like medicines used to treat severe pain (e.g. methadone, fentanyl); sleeping pills (e.g. alprazolam, zolpidem) and also midazolam administered by injection; tranquillisers (e.g. haloperidol, risperidone, thioridazine); colchicine, a treatment for gout.
Maltese: sertraline, trazodone); - mediċini għal kontra l-fungu (e.ż. ketoconazole, itraconazole); - mediċini għal kontra l-istamina (e.ż. loratadine, fexofenadine); - mediċini antiretrovirali, inklużi mpedituri protejaż HIV (amprenavir, atazanavir, darunavir,
English: PHARMACEUTICAL PARTICULARS
Maltese: PROPRJETAJIET FARMAKOLOĠIKU
English: Across dose groups, ritonavir oral clearance (CL/F/m2) declined with age with median values of 9.0 L/h/m2 in children less than 3 months of age, 7.8 L/h/m2 in children between 3 and 6 months of age and 4.4 L/h/m2 in children between 6 and 24 months of age.
Maltese: L/h/m² fi tfal ta' inqas minn 3 xhur fl-età, 7.8 L/h/m² fi tfal ta'l-età ta' bejn it-3 xhur u s-6 xhur u 4.4 L/h/m² fi tfal ta' età ta' bejn is-6 xhur u l-24 xhar.
English: 600q12h ↓ 66% ↓ 62% Bupropion is primarily metabolised by CYP2B6.
Maltese: Bupropion huwa primarjament metabolizzat b' CYP2B6.
English: Pharmacokinetic data indicate that no dose adjustment is necessary in patients with mild to moderate hepatic impairment (see section 5.2).
Maltese: Informazzjoni farmakokinetika tindika li m'hemmx bżonn ta' aġġustament tad-doża f'pazjenti li jbatu minn indeboliment tal-fwied li jvarja minn ħafif għal moderat (ara sezzjoni 5.2).
English: Interactions between ritonavir and protease inhibitors, antiretroviral agents other than protease inhibitors and other non-antiretroviral medicinal products are listed in the tables below.
Maltese: Interazzjonijiet bejn ritonavir u impedituri protejaż, aġenti antiretrovirali minbarra impedituri protejaż u prodotti mediċinali oħra li m'humiex antiretrovirali huma mniżżla fit-tabelli t'hawn taħt.
English: The reduction of the rifabutin dose to 150 mg 3 times per week may be indicated for select PIs when co-administered with ritonavir as a pharmacokinetic enhancer.
Maltese: Jista' jiġi indikat li d-doża ta' rifabutin tiġi mnaqqsa għal 150 mg 3 darbiet fil-ġimgħa f'każ ta' ċerti PIs meta jiġu użati flimkien ma' ritonavir dożat biex iżid l-effett farmakokinetiku.
English: Concomitant use of ritonavir (500 mg twice daily) dosed as an antiretroviral agent and rifabutin due to an increase of rifabutin serum concentrations and risk of adverse reactions including uveitis (see section
Maltese: L-użu ta' ritonavir (500 mg darbtejn kuljum) mogħti f'doża bħala aġent antiretrovirali flimkien ma' rifabutin minħabba żieda fil-konċentrazzjoni fis-serum ta' rifabutin u riskju ta' reazzjonijiet avversi, li jinkludu l-inflammazzjoni tal-uvea (ara sezzjoni 4.4).
English: Pancreatitis has been observed in patients receiving ritonavir therapy, including those who developed hypertriglyceridemia.
Maltese: Il-pankreatite ġiet innutata f'pazjenti li kienu qegħdin jirċievu t-terapija b'Ritonavir, inkluż dawk li żviluppaw l-ipertrigliċeridemija.